Table 1.
Characteristics of studies included in review of antibody and cellular therapies for treatment of covid-19. Values are numbers (percentages) of studies unless specified otherwise
| Study characteristics | |
|---|---|
| Registered | 47 (100%) |
| Publication status: | |
| Preprint | 16 (34%) |
| Published | 30 (64%) |
| Unpublished | 1 (2%) |
| Median (IQR) No of patients | 105.0 (58-431) |
| Country: | |
| United States | 16 (34%) |
| India | 5 (11%) |
| Brazil | 4 (9%) |
| China | 3 (6%) |
| United Kingdom | 3 (6%) |
| Intensity of care: | |
| Outpatient | 10 (21%) |
| Inpatient | 37 (79%) |
| ICU | 3 (6%) |
| Severity of illness: | |
| Mild/moderate | 9 (19%) |
| Severe/critical | 24 (51%) |
| Median (IQR) percentage of patients receiving mechanical ventilation | 10.0 (0-56.0) |
IQR = interquartile range. ICU = intensive care unit